ArticleClinical trials (London, England)2013
How good does the science have to be in proposals submitted to Institutional Review Boards? An interview study of Institutional Review Board personnel.
Article in Clinical trials (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- A Scoping Review of Empirical Research on Research Ethics Board Membership and Expertise.Journal of empirical research on human research ethics : JERHRE · 2025Article
- Standards of evidence for institutional review board decision-making.Accountability in research · 2021Article
- A Qualitative Study on Experiences and Perspectives of Members of a Dutch Medical Research Ethics Committee.HEC forum : an interdisciplinary journal on hospitals' ethical and legal issues · 2020Article
- Differences and structural weaknesses of institutional mechanisms for health research ethics: Burkina Faso, Palestine, Peru, and Democratic Republic of the Congo.BMC medical ethics · 2018Article
- How much is a child worth? Providers' and patients' views and responses concerning ethical and policy challenges in paying for ART.PloS one · 2017Article
- Deciding how many embryos to transfer: ongoing challenges and dilemmas.Reproductive biomedicine & society online · 2016Article
- Buying and selling human eggs: infertility providers' ethical and other concerns regarding egg donor agencies.BMC medical ethics · 2016Article
- Reducing the number of fetuses in a pregnancy: providers' and patients' views of challenges.Human reproduction (Oxford, England) · 2016Article
- Institutional Review Board Use of Outside Experts: A National Survey.AJOB empirical bioethicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundInstitutional Review Boards (IRBs) have been increasingly criticized for how they review protocols, but how IRBs perceive, and make decisions about, the quality of the science of protocols has not been examined. PURPOSE: To explore how and when IRBs view and make decisions about the quality of the science of studies they review.
methodsI contacted the leadership of 60 IRBs (every fourth one in the list of the top 240 institutions by National Institutes of Health (NIH) funding) and interviewed IRB chairs, co-chairs, administrators, and a director from 34 IRBs (response rate = 55%), and an additional 7 members.
resultsInterviewees faced several ambiguities and questions concerning the quality of the science of protocols. IRBs are often not sure how and to what extent to evaluate the science of protocols, whether the science should be 'good enough' (and if so, what that means) versus as good as possible. Federal regulations state that IRBs should ensure that risks are minimized, and commensurate with benefits. Thus, at times IRBs feel that changing the science is ethically necessary. But IRBs also then struggle with whether to adopt a higher threshold (1) that social and thus scientific benefits be maximized and (2) that scientific efforts and resources should not be wasted. Committees face dilemmas - for example, if a 'perfect' study is not feasible. For protocols already approved elsewhere (e.g., by the NIH), IRBs vary in how much they feel they can request alterations, and sometimes make changes nonetheless. Larger institutional contexts and biases can shape these issues, and IRBs differ in how much they are 'pro-research', and have sufficient expertise. IRBs at times also approve studies despite reservations about the science. LIMITATIONS: This study includes interviews with IRBs, but not observations of IRB meetings.
conclusionsIRBs often face ambiguities and conflicting goals in assessing scientific quality. Many IRBs try to improve the science beyond what the regulations mandate. These data have important implications for improving practice, education, research, and policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.